Phase 2 study of aflibercept for the treatment of advanced ovarian cancer with ascites - MPR
Links shared publicly online about this topic.
- 1,977total visits
Phase 2 study of aflibercept for the treatment of advanced ovarian cancer with ascites - MPR
empr.com —
Sanofi-aventis and Regeneron Pharmaceuticals announced data from a Phase 2 trial for their fusion protein product, aflibercept (VEGF Trap), in the treatment of advanced ovarian cancer patients with recurrent symptomatic malignant ascites (SMA).
View full resource at empr.com
Tags: Cancer, Ovarian Cancer, Pharma, Phase 2 Clinical Trial, Women's Health, Sanofi-Aventis, News
Most Recently Shared on June 11, 2009 at 6:34 pm By:
MPR News: Phase 2 study of aflibercept for the treatment of advanced ovarian cancer with ascites: Sanof.. http://tinyurl.com/mobhuq
Advertisement
